Dissolution studies on ampicillin embonate and amoxycillin embonate

Saesmaa, Tarja; Tötterman, Ann Marie

doi:10.1016/0731-7085(90)80007-c

Cited by 8 publications

(7 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pamoic acid (PA) is a potent GPR35 agonist that exhibits an antinociceptive property mediated through GPR35 14 . In contrast, pamoic acid is considered to be inert 15 and currently in use to improve the dissolution of pharmaceutical formulations 16 . GPR35 activation by pamoic acid may increase the phosphorylation of ERK1/2, which in turn initiates an anti-inflammatory signal by suppressing NF-κB-dependent inflammatory genes 17 .…”

Section: Pamoic Acid Is a Potent Ligand For G Protein Coupled Receptomentioning

confidence: 99%

Activation of GPR35 protects against cerebral ischemia by recruiting monocyte-derived macrophages

Sharmin

Abir

Potol

et al. 2020

Sci Rep

View full text Add to dashboard Cite

after MCAO (Fig. 7B and Supplementary Fig. 1B) although the pAkt concentration was unaffected 48 h after the MCAO. Therefore, we conclude that activation of GPR35 on monocyte/macrophages by its ligand pamoic acid reprograms these cell types into neuroprotective pathways. Method Mice. Male Swiss albino mice (8-12 weeks) were collected from the North South University (NSU) animal house and were maintained under standard environmental conditions (temperature 23.0 ± 2.0 °C, relative humidity: 55-65% and 12 h light and dark cycle). All experiments were carried out according to the institutional guideline and were approved by the NSU Institutional Animal Care and Use Committee (IACUC).

show abstract

Section: Pamoic Acid Is a Potent Ligand For G Protein Coupled Receptomentioning

confidence: 99%

Activation of GPR35 protects against cerebral ischemia by recruiting monocyte-derived macrophages

Sharmin

Abir

Potol

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

“…The acetate salt was used in the first formulations (daily and monthly) of triptorelin to be developed [22,23]. Pamoate salts are widely used to enable slow-release formulations of pharmaceutical agents [24,25,26,27], having physicochemical properties suitable for sustained release. Therefore, a triptorelin pamoate salt was also developed, which additionally facilitated a more consistent production.…”

Section: Introductionmentioning

confidence: 99%

A 6-Month Trial of the Efficacy and Safety of Triptorelin Pamoate (11.25 mg) Every 3 Months in Children with Precocious Puberty: A Retrospective Comparison with Triptorelin Acetate

Zénaty

Blumberg²,

Liyanage³

et al. 2016

Horm Res Paediatr

View full text Add to dashboard Cite

Background/Aims: To evaluate the efficacy and safety of a triptorelin pamoate (11.25 mg) 3-month formulation in the management of central precocious puberty (CPP) (TP Study) and to retrospectively compare it with a triptorelin acetate (11.25 mg) 3-month formulation (TA Study). Methods: We conducted two phase III, multicentre, single-stage, non-comparative, open-label studies. In the TP Study, patients with CPP received an intramuscular injection of triptorelin pamoate 11.25 mg at baseline and 3 months after baseline. Hormonal changes as well as safety and efficacy endpoints were measured at baseline, 3 months, and 6 months. Results: The baseline characteristics of the 37 patients in the TP Study were similar to those of the TA Study population. A suppressed luteinising hormone (LH) response (LH peak ≤3 IU/l) to the gonadotrophin-releasing hormone test at 3 months (primary endpoint) occurred in 83.8 and 82.8% of the cases in the TP and the TA Study, respectively. At 6 months, a suppressed LH response occurred in 86.5 and 96.8% of the cases in the TP and the TA Study, respectively. Pubertal development was slowed in both studies. Adverse events were mild to moderate and resolved without sequelae in the TP Study. Conclusion: Triptorelin pamoate 11.25 mg administered at 3-month intervals is an effective and well-tolerated treatment in patients with CPP. The efficacy and safety profiles appear similar to those reported in the literature for triptorelin acetate 11.25 mg.

show abstract

“…Studies on amoxicillin solubility in different solvents with varying values of pH showed that due to the zwitterion ion effect at pH < 9, the ionic charges of the carboxylic acid (negative pK a = 2.87) and the amine (positive pK a = 7.28) will counteract each other and cause the antibiotic to be less soluble (Saesmaa & Tötterman, ). Hence, the mechanism of the drug release can be explained by accounting for the role of the PEI under conditions of varying pH and temperature.…”

Section: Resultsmentioning

confidence: 99%

Functionalized diamond nanoparticles as a drug delivery system: Loading and release study

et al. 2019

View full text Add to dashboard Cite

Urinary tract infections (UTIs) are the second most common infectious disease in the United States, costing about $ 3.5 billion annually in treatment. As resistance to antibiotics becomes more common, a greater need for alternative treatments, including low‐dosage and cellular‐targeted antibiotic for treating UTIs, is required. Nanodiamond particles (NDPs) are attractive drug delivery platforms because of their stable, inert core and reactive but functionalizable surfaces. In addition, diamond nanoparticles show multiplicity of stable optical emission wavelengths offering a strong possibility that one or more of optical emissions can be used for optical transduction based biosensing applications. Recently and for the first time, a stable amoxicillin loading on purified and polyethyleneimine (PEI)‐functionalized NDPs has been demonstrated through our research. This research paper describes further study on the amoxicillin‐loaded NDPs by quantifying the amoxicillin loading on 6 and 25 nm NDPs and study of amoxicillin release at different pH as well as investigation of PEI release if any from these NDPs. As PEI is not detectable by UV–Vis spectrophotometer, we developed a technique of attaching copper ions to PEI polymer so that PEI can be traced and detected in the presence of amoxicillin by UV–Vis spectroscopy. The results showed that 1 g PEI‐functionalized 6 or 25 nm NDPs produced successful loading of 19 and 48 mg amoxicillin, respectively, as demonstrated by FTIR, dynamic light scattering (DLS) and UV–Vis characterization. The mechanism of drug release with respect to PEI is explained, and results show almost 85% of the drug is released in 20 hr in pH 4 at the body temperature. The results also demonstrated that there is no PEI release from the 25 nm NDPs, when the amoxicillin is released, which can be a therapeutic benefit property for drug delivery.

show abstract

Dissolution studies on ampicillin embonate and amoxycillin embonate

Cited by 8 publications

References 14 publications

Activation of GPR35 protects against cerebral ischemia by recruiting monocyte-derived macrophages

Activation of GPR35 protects against cerebral ischemia by recruiting monocyte-derived macrophages

A 6-Month Trial of the Efficacy and Safety of Triptorelin Pamoate (11.25 mg) Every 3 Months in Children with Precocious Puberty: A Retrospective Comparison with Triptorelin Acetate

Functionalized diamond nanoparticles as a drug delivery system: Loading and release study

Contact Info

Product

Resources

About